You are here:
Evaluating PFAS Human Health Hazard Data Availability: EPA Assessment Portfolio and Evidence Maps
Citation:
Owens, E., L. Carlson, A. Shirke, E. Radke-Farabaugh, AND A. Kraft. Evaluating PFAS Human Health Hazard Data Availability: EPA Assessment Portfolio and Evidence Maps. Toxicology and Risk Assessment Conference, Dayton, OH, April 24 - 27, 2023.
Impact/Purpose:
EPA’s commitment to addressing the challenge of environmental PFAS contamination includes ensuring science-based decision-making, in part by filling gaps in understanding of the potential human health hazards associated with PFAS exposures. EPA’s Office of Research and Development (ORD) under the Health and Environmental Risk Assessment (HERA) Program is advancing the science of human health assessment of PFAS through development of a portfolio of human health assessment products and implementation of rigorous systematic evidence mapping of human epidemiological and experimental animal data for individual PFAS.
Description:
Over the last several decades, public health agencies at the state and federal level, including the United States Environmental Protection Agency (EPA), Food and Drug Administration (FDA), and Agency for Toxic Substances and Disease Registry (ATSDR) have worked to understand and reduce the environmental and human health effects of per- and polyfluoroalkyl substances (PFAS). A session titled "Federal and State Approaches for Addressing Exposure of Per- and Polyfluoroalkyl Substances (PFAS)" at the 2023 Toxicology and Risk Assessment Conference will provide an opportunity for representatives from federal and state agencies to present ongoing efforts to address exposure and evaluate health effects to a wide range of PFAS and engage in a discussion on how to overcome current specific challenges associated with PFAS exposure and health risk assessments.